analysts eyes on agenix

Agenix reports growing interest from analysts
15:24, Monday, June 25, 2007

Sydney - Monday - June 25: (RWE Australian Business News) -
Agenix Ltd (ASX code: AGX) today said it was aware that sharemarket
analysts were taking an increasing interest in the company.
The company was responding to an ASX query which noted a rise in
its shares from a low of 13c on Wednesday June 20 to 20c today.
"Agenix believes that the share price increase may be the result
of a wider appreciation of the value to Agenix of its recent acquisition
of Chinese bio-pharmaceutical group SHRG," directors said.
They also noted Agenix's announcement on May 18 about an
interview by Aegis Equities Research with Agenix CEO and managing
director Mr Neil Leggett.
"Mr Leggett discussed the independent valuation of SHRG's GMP
manufacturing facility and anti-hepatitis B virus drug (which has
completed clinical trials and is expected to be generating sales in the
second half of calendar year 2007).
"The valuation was $56 million," the directors said.
They noted this valuation did not include SHRG's remaining
product pipeline, which included:
* a new-generation anti-hepatitis B virus drug,
* an anti-colon cancer drug,
* an anti-liver cancer drug, and
* an anti-HIV drug.
The valuation also did not take into account use of the unused
capacity from the GMP manufacturing facility.